Predix Initiates Trial of Receptor Antagonist for Pulmonary Hypertension

Predix Pharmaceuticals has begun Phase I studies with PRX-08066, its highly selective, proprietary 5-HT2B receptor antagonist for the treatment of pulmonary hypertension (PH) and hypoxia-induced PH syndromes caused by chronic obstructive pulmonary disease and mountain sickness.

This drug candidate is the third compound Predix has discovered and advanced into clinical development in less than three years.

As a selective 5-HT2B antagonist, PRX-008066 has the potential to act both as a vasodilator of pulmonary but not systemic blood vessels, and as a disease-modifying agent to slow the progression of the disease. The primary objectives of the Phase I study are to evaluate the safety and tolerability of the compound and to obtain pharmacokinetic data in humans.